TWP
KRYS icon

Tempus Wealth Planning’s Krystal Biotech KRYS Stock Holding History

Tempus Wealth Planning’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,379
Closed -$327K – 284
2025
Q2 		$327K Buy
+2,379
New +$349K 0.08% 200

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Tempus Wealth Planning's KRYS Position: Q3 2025 in Review

Tempus Wealth Planning sold out of Krystal Biotech (KRYS) in Q3 2025, closing a stake of 2,379 shares — an estimated $327K sold.

Tempus Wealth Planning first reported a position in KRYS in Q2 2025 and held it in 1 quarter. The position peaked at $327K in Q2 2025. 284 funds tracked by Wall St. Rank hold KRYS as of Q3 2025.

  • Tempus Wealth Planning reported no remaining Krystal Biotech position as of Q3 2025 after selling out during the quarter.
  • Tempus Wealth Planning sold 2,379 Krystal Biotech shares in Q3 2025, an estimated $327K.
  • Tempus Wealth Planning first reported a position in Krystal Biotech in Q2 2025 and held it in 1 quarter.
  • Tempus Wealth Planning's Krystal Biotech position peaked at $327K in Q2 2025.
  • 284 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2025.

Based on Tempus Wealth Planning's 13F filing for Q3 2025, filed 6 Nov 2025.